From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Clinical trial | Phase | α-PD-1/PD-L1 | Radiotherapy | Cancer type | Primary outcome measures |
---|---|---|---|---|---|
NCT02608385 | 1 | Pembrolizumab | SBRT | Solid tumors | Recommended SBRT dose |
NCT02621398 | 1 | Pembrolizumab | Concurrent chemoradiation | NSCLC | MTD and DLT |
NCT02434081 | 2 | Nivolumab | Concurrent chemoradiation | NSCLC | Safety |
NCT02586207 | 1 | Pembrolizumab | Concurrent chemoradiation | HNSCC | Safety |
NCT02383212 | 1 | Cemiplimab | Concurrent chemoradiation | Solid tumors | Safety, DLT |
NCT02402920 | 1 | Pembrolizumab | Concurrent chemoradiation; Concurrent radiation | SCLC | DLT |
NCT02904954 | 2 | Durvalumab | SBRT | NSCLC | Pathological response rate |
NCT02125461 | 3 | Durvalumab | Concurrent chemoradiation | NSCLC | PFS, OS |
NCT02684253 | 2 | Nivolumab | SBRT | HNSCC | BOR |
NCT02952586 | 3 | Avelumab | Concurrent chemoradiation | HNSCC | PFS |